BioCentury | Jan 19, 2018
Company News

Context acquires onapristone from Arno

...the 1990s. He said Arno developed and tested Apristor, an extended release formulation of the progestin receptor...
...Therapeutics Inc., Flemington, N.J. Context Therapeutics, Philadelphia, Pa. Business: Cancer Allison Johnson onapristone ER Arno Therapeutics Inc. Context Therapeutics Schering AG Progestin receptor Apristor...
BioCentury | Jan 12, 2017
Clinical News

Onapristone: Ph II halted

...N.J. Invivis Pharmaceuticals Inc. , Bridgewater, N.J. Product: Onapristone Business: Cancer Molecular target: Progestin receptor Description: Progestin receptor...
...II dose; safety and pharmacokinetics Status: Phase II halted Milestone: NA Julian Zhu onapristone Arno Therapeutics Inc. Invivis Pharmaceuticals Inc. Progestin receptor...
BioCentury | Apr 25, 2016
Clinical News

Onapristone: Phase I/II discontinued

...N.J. Invivis Pharmaceuticals Inc. , Bridgewater, N.J. Product: Onapristone Business: Cancer Molecular target: Progestin receptor Description: Progestin receptor...
BioCentury | Aug 24, 2015
Clinical News

Onapristone ER: Phase I/II amended

...Bridgewater, N.J. Product: Onapristone ER Business: Cancer Molecular target: Progestin receptor Description: Extended-release formulation of a progestin receptor...
BioCentury | Jul 20, 2015
Clinical News

Onapristone: Additional Phase I data

...N.J. Invivis Pharmaceuticals Inc. , Bridgewater, N.J. Product: Onapristone Business: Cancer Molecular target: Progestin receptor Description: Progestin receptor...
BioCentury | Jul 20, 2015
Clinical News

Onapristone ER: Phase I data

...Bridgewater, N.J. Product: Onapristone ER Business: Cancer Molecular target: Progestin receptor Description: Extended-release formulation of a progestin receptor...
BioCentury | May 11, 2015
Clinical News

Onapristone: Phase I data

...N.J. Invivis Pharmaceuticals Inc. , Bridgewater, N.J. Product: Onapristone Business: Cancer Molecular target: Progestin receptor Description: Progestin receptor...
BioCentury | Apr 14, 2014
Clinical News

Onapristone ER: Phase I/II started

...Bridgewater, N.J. Product: Onapristone ER Business: Cancer Molecular target: Progestin receptor Description: Extended-release formulation of a progestin receptor...
BioCentury | Mar 10, 2014
Company News

Arno, University of Minnesota deal

...derived from archived breast cancer tissue samples, can potentially identify progesterone-simulated pathway activation. Onapristone, a progestin receptor...
BioCentury | Jan 27, 2014
Clinical News

Onapristone: Phase I started

...N.J. Invivis Pharmaceuticals Inc. , Bridgewater, N.J. Product: Onapristone Business: Cancer Molecular target: Progestin receptor Description: Progestin receptor...
Items per page:
1 - 10 of 15